<SEC-DOCUMENT>0001558370-23-000003.txt : 20230103
<SEC-HEADER>0001558370-23-000003.hdr.sgml : 20230103
<ACCEPTANCE-DATETIME>20230103065719
ACCESSION NUMBER:		0001558370-23-000003
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230103
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230103
DATE AS OF CHANGE:		20230103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		23500164

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20230103x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 1/3/2023 11:08:53 AM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 7a45a2e4-4c9e-4184-876b-df4b1e742721 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20230103" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:EntityCentralIndexKey" id="Tc_7CQWgRnOLUWkbVL0KTzZRA_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:AmendmentFlag" id="Tc_xGl02ovOlUqL-PzU8l7t1A_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20230103.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0e9ca0c2_ebd9_4bd2_825b_93ebacf24761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:DocumentType" id="Narr_c5AqvKBPKUirEtjg12SiKg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_0LDOWSRbqU6DZTVpGafK4g"><b style="font-weight:bold;">January&#160;3, 2023</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:EntityRegistrantName" id="Narr_loVoJoghNEKRXvL3nmOY0A"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_c8Hk9cv2ZEalu2ITJHX1qw_2_0"></a><a id="Tc_0kpLF9AaqEeVHKrdacymjQ_2_2"></a><a id="Tc_MNN-FQDvZUOBCQTGOuFPiA_2_4"></a><a id="Tc_cA8pLB0F7k-NowCxbPiHfw_6_0"></a><a id="Tc_SddJV12UEEu1A0Fi_ReZvA_7_0"></a><a id="Tc_wK0eujUcgEuxhosnct-15Q_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_qPYa6gjUCUOD-bKGjo1DTQ_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:EntityFileNumber" id="Tc_qjl3Ag90AkqZSsKgwn1A1A_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:EntityTaxIdentificationNumber" id="Tc_mvS2xBec70Gfo8-c7mx1zw_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:EntityAddressAddressLine1" id="Tc_S01c6yh3zEGLHouxwR9cng_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:EntityAddressAddressLine2" id="Tc_D7XHinna2kyoJZLu4IQx2w_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:EntityAddressCityOrTown" id="Narr_OCw42qVb40mT6mdvmSRkAA"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:EntityAddressStateOrProvince" id="Narr_agBYJKqi60ux6sIhOIUjYA"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:EntityAddressPostalZipCode" id="Tc_gidCeHCBdEKJP3iYTsCC8A_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:CityAreaCode" id="Narr_hdAz83zmd0yNXxxxWBRliA"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:LocalPhoneNumber" id="Narr_O8ymW9Sh7U6f7x2Tikxnog"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_gZnofv5tVke4xAk56oTCWQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_hf81jF_RdkmqNi1pJdXSjg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_x-WPTai3GkazESk_bdRtiw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_CeNZfQaRfUu4Ka4pYWV7ZQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_l9nP7FSWIUm9V7aMOPA2DQ_1_0"></a><a id="Tc_0pqberRshki38I4IYhYyxg_1_1"></a><a id="Tc_N9yQXzOHgECyZL64Jmhq_Q_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:Security12bTitle" id="Tc_44sXdPL81UWh-6za0_bhyQ_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" name="dei:TradingSymbol" id="Tc_MocrQIA-hkGBI11nKI7rMg_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_W_2IS8EbeEeB4oCnMNy4wA_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_GOj-dbmbOkyxSByW6cbJmw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:Times New Roman;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;7.01</b></span>Regulation FD Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On January&#160;3, 2023, Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) issued a press release containing a copy of a letter to its stockholders discussing recent regulatory and clinical developments. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (&#8220;Current Report&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;9.01</b></span>Financial Statements and Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit No.</p></td><td style="vertical-align:bottom;width:0.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20230103xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated January&#160;3, 2023</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January&#160;3, 2023</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20230103xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 1/3/2023 11:08:48 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><img src="plx-20230103xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:39.15pt;width:128.45pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><a name="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><a name="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><b style="font-weight:bold;">Protalix BioTherapeutics Issues 2023 Letter to Stockholders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CARMIEL, Israel</b>, January&#160;3, 2023 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<sup style="font-size:9pt;vertical-align:top;">&#174;</sup> plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders and the investment community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 0pt 10pt 0pt;">January&#160;3, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Dear Protalix Shareholders,</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">2022 was a strong year for Protalix, and I would like to take a moment to reflect on the significant progress we have made. Together with our development and commercialization partner, Chiesi, we executed on key regulatory milestones with the submission of marketing authorization applications in the United States and the European Union for PRX-102 for the treatment of adult patients with Fabry disease, bringing us one step closer to the potential approval and commercialization of this important treatment option. I continue to be immensely grateful to our team and our partners for their steadfast dedication to bringing PRX-102 to patients. I am proud of our accomplishments in 2022, highlighted below, and look forward to continued success in 2023 as we continue to work towards meaningful, value-adding milestones and transformational catalysts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Regulatory Advancements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Together with Chiesi, we submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in February 2022. As you know, our PRX-102 phase&#160;III clinical program consists of extensive data from three phase III clinical trials, the <i style="font-style:italic;">BRIDGE</i> study which analyzed 1&#160;mg/kg of PRX-102 every two weeks dosing, the <i style="font-style:italic;">BRIGHT</i> study which analyzed 2&#160;mg/kg of PRX-102 every four weeks dosing and the <i style="font-style:italic;">BALANCE</i> study which analyzed 1&#160;mg/kg of PRX-102 every two weeks dosing. The MAA includes final data from our <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> clinical trials; and final data from our phase&#160;I/II clinical trial generated from na&#239;ve/untreated patients including the related extension study using 1&#160;mg/kg of PRX-102 every two weeks dosing. The EMA is currently reviewing the PRX-102 MAA, and interactions with the EMA are ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">In addition, we, together with Chiesi, resubmitted a Biologics License Application (BLA) to the U.S.&#160;Food and Drug Administration (FDA) in November 2022. The FDA accepted the submission for review and set an action date of May&#160;9, 2023 under the Prescription Drug User Fee Act (PDUFA). The BLA resubmission includes a comprehensive set of clinical and manufacturing data, identical to the one submitted to the EMA, which was compiled from studies that involved more than 140 Fabry disease patients with up to five years of follow up, including all three completed studies in the PRX-102 phase&#160;III clinical program,. The BLA resubmission also includes safety data compiled from our ongoing phase&#160;III extension studies of PRX-102. If PRX-102 is approved by the FDA, Protalix will be eligible to receive a milestone payment from Chiesi.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Clinical Advancements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">With the successful readouts of our <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BALANCE</i> studies in 2022, we concluded our phase&#160;III clinical program which supported our regulatory submissions to the FDA and EMA as mentioned above. Final results of the data generated in the <i style="font-style:italic;">BALANCE</i> study, completed in July 2022, demonstrated that PRX-102 was statistically non-inferior to agalsidase beta, measured by estimated glomerular filtration rate (eGFR) slope. Similarly, final results from the <i style="font-style:italic;">BRIGHT</i> study were announced in March 2022 and demonstrated stable disease with PRX-102 treatment as measured by eGFR slope and plasma lyso-Gb<sub style="font-size:9pt;vertical-align:sub;">3</sub>. Results from both studies showed a favorable tolerability profile for PRX-102, which is consistent with results from our prior trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">We are also progressing with our clinical development program for PRX-115, our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically-modified enzyme under development for the potential treatment of severe gout. Gout is the most common inflammatory arthritis in the United States, affecting an estimated 9.2&#160;million adults. Expressed using ProCellEx<sup style="font-size:9pt;vertical-align:top;">&#174;</sup>, our proprietary plant cell-based protein expression system, PRX-115 is an optimized recombinant uricase enzyme that we are designing to lower uric acid levels while having low immunogenicity and increased half-life in the circulation. Pre-clinical data demonstrates stable PK profile and long half-life, low immunogenic risk and high specific activity, supporting the potential of PRX-115 to be a safe and effective treatment for severe gout. Preliminary results of the first stage of one-month multiple dosing toxicity studies of PRX-115 in two species show no indication of safety concerns, and our current development plan goal is to initiate a phase&#160;I clinical trial in the first quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Looking Forward </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">I am excited about our accomplishments in 2022 and look forward to what the future holds as we navigate the company through 2023 and beyond. We believe PRX-102, if approved, has the potential to meaningfully improve the quality of life for many Fabry patients and their families and, together with Chiesi, we are preparing for the anticipated commercial launch. Fabry disease represents a tremendous opportunity in a multi-billion dollar market ready for a potentially better treatment option. We are also making progress with PRX-115 and our other earlier stage pipeline programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">We thank our employees for their tireless efforts in driving Protalix forward and building on our scientific foundation. We also thank our Board of Directors for their valuable support and guidance in shaping the company&#8217;s operations and direction. Chiesi deserves our gratitude for their professionalism and the close collaboration we enjoy. Finally, we would like to thank you, our shareholders, for your continued support and look forward to sharing our future successes with you.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Sincerely,</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Dror Bashan, President &amp; Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human &#945;-Galactosidase-A protein for the treatment of Fabry disease; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: that the FDA might not grant marketing approval for PRX<font style="color:#242424;">-</font>102 by the PDUFA date or at all and, if approved, whether PRX<font style="color:#242424;">-</font>102 will may have significant limitations on its use; risks related to the timing, progress and likelihood of final approval by the FDA and European Medicines Agency (EMA) of the resubmitted Biologics License Application (BLA) and of a Marketing Authorization Application, respectively; risks related to the commercial success of PRX-102, and of our other product and product candidates, if approved; the likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;margin:0pt;">administrative expenses and working capital; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the amount and sufficiency of our cash, cash equivalents and short-term deposits; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><b style="color:#373737;font-weight:bold;">Investor Contact</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><font style="color:#373737;">Chuck Padala</font><font style="color:#373737;">, Managing Director</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><font style="color:#373737;">LifeSci Advisors</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><font style="color:#373737;">646-627-8390</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><font style="color:#0000ff;">chuck@lifesciadvisors.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><b style="color:#373737;font-weight:bold;">Source: Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><font style="margin-bottom:7.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="color:#373737;">###</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:avoid;width:75.81%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>plx-20230103xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20230103xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T *L# 2(  A$! Q$!_\0
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M@F]^R5;Q^,?C5\<?'FH#SM6&O-HELTG+6]M%G"#T!"Q_]\4 :=C^S7\4O%L
MO_&WQU\1VFIR#<;/PH18VL!_N@K@N![@5C^)4^-W[,5NWB%/$<GQA\!VOSZA
M8ZC"L6J6L/\ %(DB_?P.23GW4#)'UC3)8TFC=)$61&!5E89!!Z@B@#R;6=9U
MKX]?"_0M>^$OCB'PRM[(MQ_:$]@ET6B"LKPM&WW7#XSZ%2.]?/\ =7WQ]M/C
M_9?"T_&"V>[NM(;5QJ7]@6^Q5#,OE^7C.?ESG-=G^QC /!_Q"^-_@&S+?V%H
M?B!9]/BSE85F#Y0>@ 11^!IVL?\ *1;0_P#L3)/_ $8] 'M/PA\+>.?"FDZA
M#X[\90^,[Z6X$EM<PZ>EF(8MH&PJO7Y@3GWKYR_:B_:+^(.A_$W4='^&MPGV
M#P5I::QXD'DQR"4-(G[G+*2,(03MP<,Y_AKZI^(7C;3_ (<>"-<\3:HX2RTJ
MTDNI 3C=M'"CW8X4>Y%>$_L=_#6>]^%.O>+?%UM]HUOXCW$VHZ@DR\FUDW"*
M+']THS,/9QZ4 >^^"?%UAX]\(Z/XBTM_,T_5+6.[A.<D*Z@X/N.A]P:\B_;.
M^)'B/X5?!Z/6_"VI?V7J9U:TMC/Y*2_NW8AEVN".<=<9KD/V,]5O/A[KGCOX
M):S*[7GA2^>ZTIY,YFT^9MRD9[ LK?\ ;7':K7_!1#_DWV'_ +#MA_Z&U 'T
MS;L6@C+')*@D_A7A'[:/Q*\2?"KX2V.L^%M2_LO4I-;M+1I_)27,3EMZX<$<
MX'.,U[M;?\>T7^X/Y5\Q_P#!1+_DA&F_]C'8?S>@#U_XM:9XSET:/4O!6K-;
M:E9_O'TYXD>.\4<E<L,AN#C!&<XX.#7*:?\ $'5OC-X$EE\(ZN_AKQEII/VK
M3)D1@7'!1@ZDA20<-V/#5[6OW%^E>+?%_P"%NH6.KCQ_X'<67B>S!DN[88$=
M_&!\P8=-V!SG[P'J :#S<1"<+U(MM/=?JO-?B;?P;^,(\>P3Z/K,/]E^+].R
ME[82#:6QP9$![>H[9]"#7I^1CK7SA=V=K\?M MO&_@YSH?C_ $AE61 =N]P,
M^4S=""/NL>QPW'3+?XN^+/C?;V/@C0[3^P=4E1UUR_W86)%.U_+P<@'N.N3M
M!QDTKF$,8Z<5&?O-_"U]K_@]SKO$OQ0\0?$;QNOA+X<W2VT%D^=5\0>6)8X@
M#@HFX$'O_O$<< FO;=-MY+33[>"6XDNY8T"M<38WR$=6. !D^P K ^'WP^TG
MX;^'8-(TB'9$GS2S,!OG?'+N>Y_D.!Q744SNH4YQO.J[R?W+R1\5_L)_!CP'
MX]^!*ZGXC\(:-K>H_P!JW</VJ^LTEDV*5VKN(S@>E?6'A3X;>$_ @?\ X1SP
MUI.AEQM=M/LXX68>A*@$BN;^ 7P6LO@)X!'A:PU2XU>W%W+=_:+I%1\N1E<+
MQ@8KT;>OJ*#K/ES]LX?\5Y\ 1_U.,/\ -*P?VW/V<;;69[?XJ:+H,.N7^D;)
M-=T*0,(]4LTZL=A#;T7()')7W4 ^\_%SX)67Q<UOP-J5UJESIS^%=635H8[=
M%87#*5^1L]!\O4<UZ0Z!U((&#US0!YQ^SUJ_@77_ (5Z/J/P[TZSTKP[<IN%
MG:1JAAEZ.D@'_+0$8).2>#D@BO")=>'[(_[2WB&]UT/!\-/B+,MTFJA"8M/U
M$9W+(1]U6W,?HP/16Q[%\+/V=M/^#OCKQ-J_AK6[RV\/Z[)Y\WAAD0VMO-Q^
M\B/WD[C'3! _A&/1_%'A31O&^AW6C:[IUMJ^E72[)K2ZC#QN/H>A'8CD=J -
M"RO;?4K2&ZM)XKJVF4/'-"X='4]"K#@CW%<%\;/CEX:^!?A&XUG7KM/M)0BR
MTR-P;B]E_A1%Z]>K8P.]>7#]A_2= ED7P1\0_&_@:PD)+:=IFJ%K=<]E5AD?
MB372?#C]C_P)X!\11^)+PZEXR\41D,FK^)KHW<L3>J*0%4^AP2.QH S_ -CG
MX;:]X4\&ZYXL\71&W\6^-=1?6;ZW88:W1L^5&P[$!F8CMN /(-<SK'_*1;0_
M^Q,D_P#1CU]3UYI=_!"RN_CY9?%(ZI<K?VND-I*Z<$7R64LQWEOO9^;ITH \
MA_;!O;GXI>,O /P/TF=XY/$%T-3UJ6+!:"PA).3VY*L1GO&OK6G%^PAX5@B2
M*+QW\08HD4*D::^555'   3  ':O2/"?P+L?#GQE\5_$FYU6YU;6];@CM(H[
MB-%CL+=,?NHL<X.U<D^GN:].H ^&/BI\((?V/?'/@;XKZ%K&NZWI46H#3/$#
MZS=_:I1:S#:"&V@[1\W!S\P3&*]&_P""@]S%>?LZVL\$BRPRZWI[I(ARK*6)
M!!]"*]Y^)WP]TSXK> M;\)ZON%AJENT#O&!OC;JLBYXW*P##W%>;^+/V8(/&
M?P$T3X8:EXKU&2'2G@:/6/)C^T.L)/EJ1]WA2%S_ +(H ]KMO^/>+_<'\J^8
M_P#@HE_R0C3?^QCL/YO5X?LE>+0 !\?_ (@ #I_I*UL^(OV5F\8_""W\"^(?
M'^OZX\.L)JPUJ_V2W1VYVP\\;!DT >[%PD08G  R2>@XKY[\9^+-6^/?B2?P
M5X.N6MO#-NP76-<3E9!GF-#W!QC'\7^Z.?6_B-X'NO'OAY]'AURYT2WF^6X>
MTC5GE3'W,GH#WQUZ50C^%-KH_P /CX3\-:A-X=A*[9;VV17G?(^=B3_$W][L
M.!CC"9P8B%6K[B7N]>[\O+S/)]=U5KF2+X2_"F,6\<2E=6UA&^6W7HY+CJY_
MB;KGY5]M3Q'^S:OAK0-+U'P%<R67BS1EWI<,W_'^>K*_8$\@#ICY3QR/4OAK
M\,]'^&/AY-,TI"[,=]Q=R8,MP_\ >8_R X%=;MHL8PP:G&]9:]+?9[6_S/.O
M@_\ %VV^).FRV]S#_9WB2Q/EZAILGRLC X+J#SMS^(/![$^B]:\X\8?!2S\0
M>,;#Q7I>IW/AS7[8_O+JS16%P.F)%/#<<'U'!Z#'HL2E(U#'<P') QDT'90]
MJDXU=;=>Z_S[GY_^ !\"M._9KTK6-6\16>C_ !&33'D%SI>L2)JRWH+>4%C2
M3)<G9\I7!R,C%?0^KZA=R^'_ (!2^.K.]/BNYU6U\U;.=85BOC83EVF7:=Z<
M/E!CYB#GBO+?@;\4O@OI?[.?AG0O%O\ 9FHZNFG&&\TDZ6US=RN6;]WL6,EG
M(( ^HY%;'A[0]>T#X??LXV/B"WN[:^A\6,R6EZ2\]K;-;WIMXI3S\R1&-3GH
M1BF=)[+XK^,&I0^,;GPAX+\,/XNU^QACGU*22[6SL=.63F-99BK$R,/F$:*3
MCDX&*F\$?%^[U[7]0\*^(/#D_A?QI:6OVZ/3);E)X+ZWSM\VWN% #J&(5@0&
M4L,C!!KA]"\8:9\!/B?X^LO&TO\ 8^D^*-5&MZ5XAND(M)]T$4<EM)+C$<D9
MBX#D;E88Z&K6D>(K7XW?'CPSXA\+J]UX4\(V5]'/KXC9;>]N;E8T%O Q \Q4
M5"[,N5!V#.: ,'X-^+?&UW\?OB4MYX'%FMY=Z6-2SK<4HTP"R 0J O[W< #A
M<8SSTK*^ 7Q%\:0^%M?TWPEX%;Q+'I_B35Q=7^HZJMC$\C7LKB&#<CF0A67)
M.U03C)P<>E_"Q2/C[\;25(!N='P2.#_H"]*9^RK&8_AGJFY2I/B76C\RX_YB
M$W- '1^$OC7H/B3X<ZCXOO?.\/6NCM<0ZQ:ZDH673IH/]=%)C()7L5SN!4CK
M7+P_&GQ]>Z8OB&S^$E_-X89?.C235(H]6D@QGS%LRN 2.1&9 YXXSQ7G-]X$
MU7XB_#_]I#P_I",=3NO%32VL)?RQ.\<%G*(PQX&_R]N>F3S5"V\8?#=M#^U7
M?Q;^)-AK2C9+X8FU>;^UDN/^> MA'O9\\# *GKG'- 'L?CG]HO1/"GPO\/\
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M+6[^(/@+_A&_#=S-' VM:=JJ:A%8L[!4^U*$1D0L0#(NY02,X'-=-\1?BO\
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M,#% ';A%!S@9]<4AB4G)Y-%% "3V\=S$T4J++&PPR. P/U!IT<:Q(J(H1%&
MJC  HHH  @!) Y/6@(%! XS110 *@4\<5&;2$W G,2>>!M$NT;@/3/6BB@"1
MD#')YHV\#KQ110!%%9P0&0Q0QQ&0Y<H@&X^_K7D7CQ0O[37PF Z#2M<_]!M:
M** /7H+."V+F&)(BYR_EJ%W'U..M2LH=2K %2,$'O110!';VT5I&(X(DAC'.
MR-0H_(47%K%=QF.:-)8SU210P/X&BB@!ZQJF-H P,# Z#TH$:KNP.&ZBBB@
M"!5P.![5%%900-(T4,<32'+E%"EC[XZT44 /EMXY]OF1K)M.1N4'!]>:>!@4
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>plx-20230103.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/3/2023 11:08:57 AM-->
<!--Modified on: 1/3/2023 11:08:57 AM-->
<xsd:schema targetNamespace="http://protalix.com/20230103" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://protalix.com/20230103" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20230103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>plx-20230103_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/3/2023 11:08:57 AM-->
<!--Modified on: 1/3/2023 11:08:57 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20230103.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>plx-20230103_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/3/2023 11:08:57 AM-->
<!--Modified on: 1/3/2023 11:08:57 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20230103.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20230103.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638083409375591545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_638083409375591545" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638083409375591545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_638083409375591545" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638083409375591545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_638083409375591545" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638083409375591545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_638083409375591545" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638083409375591545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638083409375591545" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638083409375591545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638083409375591545" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638083409375591545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_638083409375591545" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638083409375591545" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_638083409375591545" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_638083409375601446" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_638083409375601446" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_638083409375601446" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_638083409375601446" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_638083409375601446" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_638083409375601446" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_638083409375601446" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_638083409375601446" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638083409375601446" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_638083409375601446" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_638083409375601446" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638083409375601446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_638083409375601446" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638083409375612610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638083409375612610" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638083409375612610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_638083409375612610" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638083409375612610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_638083409375612610" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139674276159664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  03,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>plx-20230103x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20230103.xsd" xlink:type="simple"/>
    <context id="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_7CQWgRnOLUWkbVL0KTzZRA_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_xGl02ovOlUqL-PzU8l7t1A_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_c5AqvKBPKUirEtjg12SiKg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_0LDOWSRbqU6DZTVpGafK4g">2023-01-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_loVoJoghNEKRXvL3nmOY0A">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_qPYa6gjUCUOD-bKGjo1DTQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_qjl3Ag90AkqZSsKgwn1A1A_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_mvS2xBec70Gfo8-c7mx1zw_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_S01c6yh3zEGLHouxwR9cng_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_D7XHinna2kyoJZLu4IQx2w_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_OCw42qVb40mT6mdvmSRkAA">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_agBYJKqi60ux6sIhOIUjYA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_gidCeHCBdEKJP3iYTsCC8A_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_hdAz83zmd0yNXxxxWBRliA">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_O8ymW9Sh7U6f7x2Tikxnog">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_gZnofv5tVke4xAk56oTCWQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_hf81jF_RdkmqNi1pJdXSjg">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_x-WPTai3GkazESk_bdRtiw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_CeNZfQaRfUu4Ka4pYWV7ZQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_44sXdPL81UWh-6za0_bhyQ_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_MocrQIA-hkGBI11nKI7rMg_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Tc_W_2IS8EbeEeB4oCnMNy4wA_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw"
      id="Narr_GOj-dbmbOkyxSByW6cbJmw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "DW(U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  I-R-6=8?]^>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>*$[8"B;-I66G#08K;.QF;+4UC?]@:R1]^R5>FS*V!]C1TL^?
M/H%:%83R$5^B#QC)8+H;;>^24&'-CD1! "1U1"M3.27<U-S[:"5-SWB (-5)
M'A#JJGH BR2U) DSL @+D76M5D)%E.3C!:_5@@^?L<\PK0![M.@H 2\YL&Z>
M&,YCW\(-,,,(HTW?!=0+,5?_Q.8.L$MR3&9)#<-0#DW.33MP>']^>LWK%L8E
MDD[A]"L90>> :W:=_-9LMKM'UM55W105+ZIFQ[FX7PF^^IA=?_C=A*W79F_^
ML?%5L&OAUUUT7U!+ P04    "  I-R-6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M "DW(U:PO5I@; 0  %@1   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9AK<^(V%(;_BL;M=-J9)+YP2U)@AB1DE]TDRP2VV\OT@[ %:&)+KB0'Z*_O
MD4ULVC7';+]@RY9>/SHZ>B71WTCUHM>,&;)-8J$'SMJ8]-IU=;AF"=47,F4"
MWBRE2JB!HEJY.E6,1GFC)'8#S^NZ">7"&?;S9U,U[,O,Q%RPJ2(Z2Q*J=C<L
MEIN!XSMO#Y[Y:FWL W?83^F*S9CYG$X5E-Q2)>()$YI+011;#IR1?WT3=&R#
MO,8OG&WTP3VQ75E(^6(+DVC@>):(Q2PT5H+"Y97=LCBV2L#QUU[4*;]I&Q[>
MOZG?YYV'SBRH9K<R_L(CLQXXEPZ)V))FL7F6F_=LWZ$<,)2QSG_)IJC;;CLD
MS+21R;XQ$"1<%%>ZW0?BH$'+/](@V#<(<N[B0SGE'35TV%=R0Y2M#6KV)N]J
MWAK@N+"C,C,*WG)H9X9W,LP@R(90$9&Q,-SLR$04HPU1Z[L&/F*KNN%>\*80
M#(X(?J#B@GBM,Q)X0>O?S5U@*P&#$C#(]5K_#Y#\,5IHHV!P_ZQC+;3;]=HV
MXZ]U2D,V<""E-5.OS!G^\)W?]7Y&R%LE>0M3K\CGNY35P>'-+\\_(A#M$J)]
M&L24*2YM!","B5++@ROE YN/;-/0=DJV#JJX'\U['C/RE"4+INJH< W/\\];
MK5:GA_!T2Y[N*3S/;,5M2D'0GFA2&RE<9ZJDH3'?DALNYVNF:,HRPT-]5J36
M1(07"&VOI.V=0@MJ4J52Y;/AC,P,#"Z1BMS*3!BU@VM4VP5<_&Z,$%Z6A)>G
M$,[IEDPBR$&^Y&$Q:8^/-J[8[9Q[W7:KU\/2[ZK$NSH%;Q1%,/?UV=L->8!Z
MY).HC1JN&)#/ M88I:WN-*9_4P33]RJ+]KX1M.*<;V2M1^.*LXQ#EOB>A_$=
M+"'^-_&5.0@3X96+L#:2#9I/'S"T:O'P48?_"NW6EH!L+C?U:QLN]YZ&+[ C
M@5^,KEH@?-SB_TLWE1J,@_S.TZ/3MD'1ZW4]'V.KU@T?M_L\4B/8Z!U'P04"
M'*1:)'S<X1]D"#&9KJ7 5HD&D>Y5]_RJU>Y@1-4RX>/^_D5Q8YB P"1))O:>
MIFNI<*$EC37#D*JUP,?]>B9C'G+#Q8H\PN13G,:U/+A*(T_E_#YNU%/%SD,(
M#X/97^R!F(B8(I^6RR/CA^LUDE6F[^,>_1791.L,R!H!<=DFP*!R^P#WYCDW
ML!^22^('/RY^(C,69I!ON]K=+:YD\Q,66SA#A"]GY'OO C9+)*6*O-(X0V$K
MZP]PFYXK&MFDF^V2A:Q-N0:!Z<.O&,C!*0%WYK<PD?$V7%.Q8D?W;@U"3[_-
MQJ/'\3-&51E\<)+!CQ.F5C9,[T#!K*UQI%34#RDNV)AFE;\'N#WOT6YA"BCP
MUPED_Y9\9/50N)0'>>5YW> 2,_R@,OP ]^H13,LHGYKW,5W5\N "1X/D'IR3
M[7\.C]0.BR8Q6X*0=]$#754<XXN"D6E^=%Y( P?Q_';-*/B$K0#OEU*:MX(]
MC9=_I@S_ 5!+ P04    "  I-R-6GZ ;\+$"  #B#   #0   'AL+W-T>6QE
M<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/ZZZ>S
M;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N6/O.
M-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NC
MSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K <
MXRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=J?$,
M:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'
MR6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D
M$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(
MT5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C
M_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O[
M"_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[7FY'
MU=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..VBB(K
MU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;
MK?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX
M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  I-R-6EXJ[',     3 @
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
M*3<C5F60>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P
M$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>L
MWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH
M>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G
M(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6
M&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O
M>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+
MX3]>?P%02P$"% ,4    "  I-R-6!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "DW(U9UA_WY[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( "DW(U:97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ *3<C5K"]6F!L!   6!$  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( "DW(U:?H!OPL0(  .(,   -              "  :\,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ *3<C5I>*NQS     $P(   L
M     ( !BP\  %]R96QS+RYR96QS4$L! A0#%     @ *3<C5APX9>H_ 0
M/ (   \              ( !=!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( "DW(U8D'INBK0   /@!   :              "  > 1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "DW(U9ED'F2&0$  ,\#
M   3              "  <42  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(   \4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20230103x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20230103x8k.htm">plx-20230103x8k.htm</File>
    <File>plx-20230103.xsd</File>
    <File>plx-20230103_lab.xml</File>
    <File>plx-20230103_pre.xml</File>
    <File>plx-20230103xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20230103x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20230103x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20230103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20230103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20230103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20230103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230103x8k.htm",
      "contextRef": "Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20230103x8k.htm",
      "contextRef": "Duration_1_3_2023_To_1_3_2023_R3xbY2RoTkqo7Q0VvtJHnw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20230103",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-23-000003-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-000003-xbrl.zip
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M(D3--"1,B*O^]TV0>/X P7:*A3>*Y,N3YYM/B/# PZ=-0, [XA%FM&\X#=L
MB'K,QW31-U:1"2,/8^/3QY]_>OC%-+\]OCX#GWFK %$!/(Z@0#Y88[$$4Q:&
MD((QXAP3 AXY]A<( ,=NR* -%YAF$N,11O(81D$<K-EP]BW#)!ZC/>!8KM6T
MFRYPG)Y]WVO?@<%X+QS+_.8X5TDP_:NG/F:R2R"-TJBWB7#?6 H1]BQKO5XW
MUFZ#\84,8#O6M_'SF[=$ 30QC02D'C* U/>B>.<S\Z"(1^G@\,V,$QW M?9]
M92K4+U/+3+7+=)JFZS0VD6\D*:KF IUHN6K%%_0'7G;ZL_C)&#C=;M>*6PTY
M>@ \<$;0*YJ#>%]/;$/4-R(<A$3%BO<M.9KWC9!L3$7 =FQ7&?GP.9DA^GM
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MI_'X4ABWG(@P33YC75M9F!MS[5-3GQ]R?>K\JE0?P8_A=:R#_P=02P,$%
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MP^8>(#XPBO3N82?<0=[RM-034RW$*2P?F;R#MY'5K99-FDAK+1@PJ[5F6*L
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M,C R,S Q,#,N>'-D4$L! A0#%     @ *3<C5NPT@ER8!0  WSX  !0
M         ( !Y@,  '!L>"TR,#(S,#$P,U]L86(N>&UL4$L! A0#%     @
M*3<C5L'!)?.5!   0"H  !0              ( !L D  '!L>"TR,#(S,#$P
M,U]P<F4N>&UL4$L! A0#%     @ *3<C5G>CEXO3%   N9H  !,
M     ( !=PX  '!L>"TR,#(S,#$P,W@X:RYH=&U02P$"% ,4    "  I-R-6
MO2VP0@$7  !Y3   %P              @ %[(P  <&QX+3(P,C,P,3 S>&5X
>.3ED,2YH=&U02P4&      4 !0!( 0  L3H

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
